Genmab A/S Files 6-K, Incorporates by Reference
Ticker: GNMSF · Form: 6-K · Filed: Dec 29, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Dec 29, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, regulatory, announcement
Related Tickers: GMAB
TL;DR
Genmab filed a 6-K on Dec 29, 2025, incorporating announcements into existing filings.
AI Summary
Genmab A/S filed a Form 6-K on December 29, 2025, to report company announcements. This filing is incorporated by reference into several of Genmab's existing S-8 registration statements, including File Nos. 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.
Why It Matters
This filing ensures that important company announcements are officially registered with the SEC and become part of Genmab's public record, potentially impacting investor awareness and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing to incorporate previously issued announcements, not indicating new material risks.
Key Players & Entities
- Genmab A/S (company) — Registrant
- December 29, 2025 (date) — Filing Date
- 333-232693 (registration_statement_file_number) — Incorporated by Reference
- 333-253519 (registration_statement_file_number) — Incorporated by Reference
- 333-262970 (registration_statement_file_number) — Incorporated by Reference
- 333-277273 (registration_statement_file_number) — Incorporated by Reference
- 333-284876 (registration_statement_file_number) — Incorporated by Reference
FAQ
What type of SEC filing is this document?
This document is a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
When was this Form 6-K filed?
This Form 6-K was filed on December 29, 2025.
What is the primary purpose of this filing?
The primary purpose is to report company announcements and to be incorporated by reference into Genmab A/S's existing registration statements.
Which registration statements does this filing get incorporated into?
This filing is incorporated by reference into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.
What is the exhibit included in this filing?
The filing includes Exhibit 99.1, which is a Company Announcement Dated December 29, 2025.
Filing Stats: 214 words · 1 min read · ~1 pages · Grade level 14.4 · Accepted 2025-12-29 08:27:51
Filing Documents
- gmab_20251229x6k.htm (6-K) — 13KB
- gmab_20251229xex99d1.htm (EX-99.1) — 25KB
- genmab_logo.jpg (GRAPHIC) — 56KB
- 0001434265-25-000112.txt ( ) — 112KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2025 COMMISSION FILE NUMBER 001-38976 Genmab AS (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab AS's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Company Announcement Dated December 29, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GENMAB AS BY s Anthony Pagano Name Anthony Pagano Title Executive Vice President Chief Financial Officer DATE December 29, 2025